Detalhe da pesquisa
1.
Preclinical characterization of ISB 1342, a CD38 × CD3 T-cell engager for relapsed/refractory multiple myeloma.
Blood
; 142(3): 260-273, 2023 07 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-37192303
2.
Design and selection of optimal ErbB-targeting bispecific antibodies in pancreatic cancer.
Front Immunol
; 14: 1168444, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37153618
3.
Fc-engineered anti-CD40 antibody enhances multiple effector functions and exhibits potent in vitro and in vivo antitumor activity against hematologic malignancies.
Blood
; 116(16): 3004-12, 2010 Oct 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-20616215
4.
The impact of Fc engineering on an anti-CD19 antibody: increased Fcgamma receptor affinity enhances B-cell clearing in nonhuman primates.
Blood
; 113(16): 3735-43, 2009 Apr 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-19109559
5.
DPP inhibition alters the CXCR3 axis and enhances NK and CD8+ T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal adenocarcinoma.
J Immunother Cancer
; 9(11)2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34737215
6.
TNF ligands: is TALL-1 a trimer or a virus-like cluster?
Nature
; 427(6973): 413-4; discussion 414, 2004 Jan 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-14749821
7.
Functionally Defective T Cells After Chemotherapy of B-Cell Malignancies Can Be Activated by the Tetravalent Bispecific CD19/CD3 Antibody AFM11.
J Immunother
; 42(5): 180-188, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31090657
8.
Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective.
Drug Discov Today
; 12(21-22): 898-910, 2007 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-17993407
9.
Highly Specific and Effective Targeting of EGFRvIII-Positive Tumors with TandAb Antibodies.
Front Oncol
; 7: 100, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28596941
10.
Trispecific antibodies for CD16A-directed NK cell engagement and dual-targeting of tumor cells.
Protein Eng Des Sel
; 30(9): 673-684, 2017 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28981915
11.
Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection.
Curr Opin Immunol
; 40: 24-35, 2016 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-26963133
12.
Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia.
Clin Cancer Res
; 22(23): 5829-5838, 2016 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27189165
13.
A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
MAbs
; 7(3): 584-604, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25875246
14.
A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells.
MAbs
; 6(3): 728-39, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-24670809
15.
Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia.
Cancer Res
; 68(19): 8049-57, 2008 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-18829563
16.
Inactivation of TNF signaling by rationally designed dominant-negative TNF variants.
Science
; 301(5641): 1895-8, 2003 Sep 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-14512626